B4084 - AvonCAP Hospital Study - 11/07/2022

B number: 
B4084
Principal applicant name: 
Catherine Hyams | University of Bristol (United Kingdom)
Co-applicants: 
Mrs Madeleine Clout
Title of project: 
AvonCAP Hospital Study
Proposal summary: 

AvonCAP is an ongoing surveillance study, which aims to record detailed information on every adult patient admitted to Bristol’s two large NHS Trusts with symptoms, signs and/or X-ray evidence of acute disease in the lungs. This includes patients with pneumonia, non-pneumonic respiratory infection, exacerbation of chronic respiratory disease (eg asthma, COPD, pulmonary fibrosis) and heart failure. Additionally, we include patients hospitalised with a positive SARS-CoV-2 test. The study is designed to provide comprehensive surveillance of all adults hospitalised with acute respiratory disease in a defined geographic area, thereby providing an accurate estimate of disease incidence. AvonCAP further aims to investigate how lung diseases may be changing during the COVID-19 pandemic, particularly those which may be preventable in the future by new vaccines. This will enable better implementation and design of public health measures, and may be used to determine national vaccination implementation policy.

Health related data is collected for study eligible adults hospitalised at NBT or UHBW NHS Trust, either via consent or under COPI regulations (the study holds CAG approval to use non-consented data). Some study patients also give their consent to provide samples e.g. saliva, nasopharyngeal swabs, etc.

This proposal will identify patients who are in both the AvonCAP and ALSPAC datasets, and allow sharing of specified data fields between the two studies for these patients. Due to the age range of AvonCAP participants, this is likely to include the parents of the Children of The 90s.

Only relevant ALSPAC data fields will be shared with the AvonCAP study team, and will include potential risk factors for lung disease (e.g. occupation and environment factors, pets), details of GP visits and COVID-19 test results. The AvonCAP study will in turn provide data fields of interest to the ALSPAC project.

This proposal allows data collected on participants in these two studies to have added value and greater contribution to the scientific aims of each project.

Impact of research: 
The AvonCAP study is producing data which has already directly impacted the clinical care of patients with COVID-19 and influenced COVID-19 vaccination strategies. Interim study findings have been presented to UK and international COVID-19 groups, including the UK Joint Committee on Vaccination and Immunisation, and the Standing Committee on Vaccination (Germany). The results of this study have been used in international and national policy decisions (eg WHO COVID-19 vaccine guideline, UK national COVID-19 vaccination policy). The study also aims to impact vaccination strategies to prevent other adult respiratory diseases, and their associated morbidity and mortality. The study will produce data which will improve the understanding of how much LRTI is vaccine preventable, either with approved or investigational vaccines, helping to inform vaccination recommendations in the future.
Date proposal received: 
Monday, 30 May, 2022
Date proposal approved: 
Monday, 30 May, 2022
Keywords: 
Clinical research/clinical practice, Respiratory - asthma, Statistical methods, BMI, Cardiovascular, Cohort studies - attrition, bias, participant engagement, ethics, Environment - enviromental exposure, pollution, Immunity, Pets, Physical - activity, fitness, function